Phase 2 Study of VX-950, Pegasys® With and Without Copegus® in Hepatitis C

Exclusion Criteria

• •Received any approved or investigational drug or drug regimen for the treatment of hepatitis C.
• •Any medical contraindications to Peg-IFN-alfa-2a or Ribavirin therapy
• •Any other cause of significant liver disease in addition to hepatitis C; this may include but is not limited to, hepatitis B, drug or alcohol-related cirrhosis, autoimmune hepatitis, hemochromatosis, Wilson's disease, Nonalcoholic Steatohepatitis or primary biliary cirrhosis.
• •Diagnosed or suspected hepatocellular carcinoma.
• •Histologic evidence of hepatic cirrhosis (including compensated cirrhosis) based on a liver biopsy taken within 2 years before Study start.
• •Alcohol/drug abuse or excessive use in the last 12 months.
• •Participation in any investigational drug study within 90 days before drug administration or participation in more than 2 drug studies in the last 12 months (exclusive of the current study).